Companies › BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BGM0504 injection GLP-1 receptor agonist | – | Phase 3 | Overweight or Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06704581 | BGM0504 injection | Phase 3 | Overweight or Obesity | Metabolic and endocrine | Mar 2026 |
No annotated target.
–
Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma Neuvosyn Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.